{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:23:36Z","timestamp":1785425016353,"version":"3.56.0"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["815628"],"award-info":[{"award-number":["815628"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Oxfendazole, a registered veterinary drug, has demonstrated broad-spectrum activity against multiple nematode species. First-in-human studies in healthy, predominantly Caucasian adults receiving a liquid formulation of oxfendazole demonstrated a favorable pharmacokinetic and safety profile, supporting its potential as a drug candidate for treating human helminth infections. To further advance its clinical development, we conducted a phase I bioavailability study using a field-applicable, immediate-release oxfendazole tablet. This trial investigated the pharmacokinetics, safety, and tolerability of the tablet formulation in healthy African adults residing in a filariasis-endemic country. Oxfendazole was administered as a single dose (100 or 400 mg) or as multiple doses (400 mg for 5 consecutive days) to 30 participants, randomized 8:2 to oxfendazole or placebo per cohort. Plasma concentrations of oxfendazole were measured using a validated high-performance liquid chromatography tandem mass spectrometry method, and pharmacokinetics were assessed using non-compartmental analysis. Peak plasma concentrations were reached after ~2.5\u20133 h. The median elimination half-life ranged from 11.6 to 13.9 h and was consistent across cohorts. Non-linear pharmacokinetics was observed, with exposure (AUC\n                      <jats:sub>\u221e<\/jats:sub>\n                      ,\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ) increasing less than dose-proportionally and showing high variability. Oxfendazole was well tolerated, with no adverse events reported and no clinically significant abnormalities in laboratory tests, vital signs, physical examinations, or electrocardiograms. These findings support the further development of oxfendazole in early proof-of-concept studies. Formulation optimization is suggested to reduce variability in exposure and improve the reliability of exposure-response assessments in future clinical trials.\n                    <\/jats:p>\n                    <jats:p>\n                      The study is registered with ClinicalTrials.gov as\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04920292\" xlink:type=\"simple\">NCT04920292<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01315-25","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:01:46Z","timestamp":1771423306000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics, safety, and tolerability of an oxfendazole tablet formulation: a phase 1, randomized, placebo-controlled trial in healthy African volunteers"],"prefix":"10.1128","volume":"70","author":[{"given":"Said","family":"Jongo","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Ackermann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adhka07","id-type":"ROR","asserted-by":"publisher"}],"name":"Swiss Tropical and Public Health Institute","place":["Allschwil, Switzerland"]},{"id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Nyaulingo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Mbaraka","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Reus","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adhka07","id-type":"ROR","asserted-by":"publisher"}],"name":"Swiss Tropical and Public Health Institute","place":["Allschwil, Switzerland"]},{"id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cicconi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adhka07","id-type":"ROR","asserted-by":"publisher"}],"name":"Swiss Tropical and Public Health Institute","place":["Allschwil, Switzerland"]},{"id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Saxena","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adhka07","id-type":"ROR","asserted-by":"publisher"}],"name":"Swiss Tropical and Public Health Institute","place":["Allschwil, Switzerland"]},{"id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaka","family":"Kassim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneth","family":"Tumbo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ally","family":"Rashid","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04js17g72","id-type":"ROR","asserted-by":"publisher"}],"name":"Ifakara Health Institute","place":["Ifakara, Tanzania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Louis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Satam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Barreira Da Silva","family":"Rocha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-9289","authenticated-orcid":true,"given":"Ivan","family":"Scandale","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Assmus","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01znkr924","id-type":"ROR","asserted-by":"publisher"}],"name":"Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University","place":["Bangkok, Thailand"]},{"id":[{"id":"https:\/\/ror.org\/052gg0110","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-3521","authenticated-orcid":true,"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03adhka07","id-type":"ROR","asserted-by":"publisher"}],"name":"Swiss Tropical and Public Health Institute","place":["Allschwil, Switzerland"]},{"id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-5812","authenticated-orcid":true,"given":"Sabine","family":"Specht","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/022mz6y25","id-type":"ROR","asserted-by":"publisher"}],"name":"Drugs for Neglected Diseases initiative","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1555241"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0001-706x(93)90010-9"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00719"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17197"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0169-4758(90)90228-v"},{"key":"e_1_3_4_7_2","unstructured":"EMEA\/MRL\/194\/97-FINAL. 1997. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/mrl-report\/oxfendazole-summary-report-3-committee-veterinary-medicinal-products_en.pdf"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008427"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09442-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02255-18"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01018-20"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-023-00088-8"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2008.11.010"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(04)03136-8"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.08.009"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01432-21"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01315-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01315-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:02:11Z","timestamp":1775048531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01315-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1128\/aac.01315-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01315-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"2025-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01315-25"}}